Developer docs
API playgroundTry for free, no card

Search company profiles

Occlutech

Full company profile

uuid0000yo2

Namestring
Occlutech
Legal namestring
Occlutech Holding AG
Websiteurl
occlutech.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Occlutech is a medical device company founded in 2003 that develops, manufactures, and commercializes minimally invasive cardiac implants based on proprietary Nitinol braiding technology. The company is legally domiciled in Switzerland as Occlutech Holding AG, with finance and distribution operations in Helsingborg, Sweden, and manufacturing and R&D facilities in Jena, Germany, and Istanbul, Turkey. Its product portfolio spans three therapeutic areas: Congenital Heart Disease (ASD, PDA, mVSD occluders), Adult Intervention and Stroke Prevention (PFO, UNI, PLD occluders), and Heart Failure (the Atrial Flow Regulator, an interatrial shunting device). Differentiated design features include a left-atrial hubless ASD Occluder and conformable braided wire architecture protected by over 200 patents.

The company sells directly in France, Germany, Italy, the Nordics, and the United Kingdom, and through a distribution partner network spanning approximately 85 countries, with over 220,000 occluders implanted across more than 70 countries. In the United States, Occlutech commercializes the ASD Occluder exclusively through B. Braun Interventional Systems Inc. following FDA approval in December 2023. Revenue is generated through per-unit hardware sales of implants and delivery accessories, supported by clinical evidence dissemination, medical congress presence, and physician education. 2025 unaudited revenue was EUR 49.4 million with approximately 85% derived from Europe and the US, representing a 15.7% CAGR over three years.

Customer segments include pediatric and adult patients with congenital heart defects, adult patients at risk of cryptogenic stroke, and heart failure patients with preserved or reduced ejection fraction who remain symptomatic despite optimal medical therapy. The company is positioning for accelerated US expansion and a potential heart failure indication for the AFR, supported by the FROST-HF pivotal study and FDA Breakthrough Device designation. A binding agreement announced in February 2026 for Alkem MedTech to acquire up to 55% of Occlutech Holding AG for EUR 99.4 million, at a total equity value of EUR 180.7 million, represents a major ownership transition expected to close by June 2026 and provide additional capital and strategic backing from Alkem Laboratories.

Short descriptiontext

Occlutech is a medical device company that develops and commercializes minimally invasive Nitinol-based cardiac implants, including occluders for congenital heart defects and the Atrial Flow Regulator for heart failure, serving interventional cardiologists across approximately 85 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHelsingborg, Sweden
HQ citystring
Helsingborg
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac occluder devices, structural heart implants, nitinol medical devices, transcatheter cardiac devices, congenital heart disease treatment
Industry2 codes
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Implants
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Occlutech generates revenue through the sale of its proprietary cardiac implants and delivery accessories. Products include occluders (ASD, PFO, PDA, mVSD, UNI, PLD) and the Atrial Flow Regulator (AFR). Revenue is derived from direct sales in key European markets and through distribution partners globally, with a growing US market following FDA approval of the ASD Occluder in 2023.

us.occlutech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1Atrial Flow Regulator (AFR)
Description

Cardiac implant designed to address unmet needs of heart failure patients through interatrial shunting

occlutech.com
+6 more records
Core offering1 text field

Occlutech designs, manufactures, and commercializes minimally invasive cardiac implants built on proprietary Nitinol braiding technology. Its portfolio includes occluders for congenital heart defects (ASD, PDA, mVSD), adult intervention occluders (PFO, UNI, PLD), and the Atrial Flow Regulator (AFR) for heart failure treatment, supported by delivery system accessories. Products are sold directly to hospitals and interventional cardiologists in key European markets and through distributor networks covering approximately 85 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Higher rate of successful defect closure with less major complications vs. comparator device in randomized trial (Kenny et al., Catheter Cardiovasc Interv 2019)
+4 more records
Product overview1 text field

Occlutech offers a broad portfolio of minimally invasive cardiac implants designed to address three main therapeutic areas: Congenital Heart Disease, Stroke Prevention & Adult Intervention, and Heart Failure. The product portfolio centers on occluder devices (ASD, PFO, PDA, mVSD, UNI, PLD) for closing various cardiac defects, and the Atrial Flow Regulator (AFR) for heart failure treatment. Supporting accessories include delivery systems (Pistol Pusher, Delivery Set III), sizing balloons, and guide wires. The company operates with a proprietary Nitinol-based braided wire technology and self-centering design across its device range. Products are sold in approximately 85 countries with manufacturing and R&D facilities in Germany and Turkey.

Product and service11 records
1ASD Occluder
CategoryCongenital Heart Disease Occluders
Description

Self-centering occluder for percutaneous transcatheter closure of ostium secundum-type atrial septal defects, featuring double discs with waist and flexible wire design for conformable deployment. Sold in over 70 countries with 220,000+ occluders implanted globally.

2PFO Occluder
CategoryAdult Intervention Occluders
Description

Occluder device for closure of Patent Foramen Ovale (PFO) to prevent cryptogenic stroke by closing the flap-like opening between the atria in adult patients.

3PDA Occluder
CategoryCongenital Heart Disease Occluders
Description

Minimally invasive transcatheter closure device for Patent Ductus Arteriosus (PDA), featuring an aortic disc connected to a conical-shaped shank made of braided Nitinol.

4mVSD Occluder
CategoryCongenital Heart Disease Occluders
Description

Occluder device designed for transcatheter closure of muscular ventricular septal defects (mVSD), a type of congenital heart defect.

5UNI Occluder
CategoryAdult Intervention Occluders
Description

Universal occluder device for various cardiac defect closures, part of Occlutech's adult intervention portfolio.

6PLD Occluder
CategoryAdult Intervention Occluders
Description

Occluder device for patent ductus ligation (PLD) procedures, part of Occlutech's adult intervention product portfolio.

7Atrial Flow Regulator (AFR)
CategoryHeart Failure Devices
Description

CE-marked cardiac implant for interatrial shunting in heart failure patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction who remain symptomatic despite optimal medical therapy. Two-disc configuration with central fenestration for controlled left-to-right atrial shunt. Available in two waist-heights, disc sizes, and fenestration diameters.

8Occlutech Pistol Pusher
CategoryImplant Delivery Accessories
Description

Delivery system accessory for precise placement and deployment of the ASD Occluder device during transcatheter procedures.

9Occlutech Delivery Set III
CategoryImplant Delivery Accessories
Description

Delivery catheter system for implanting Occlutech occluder devices through peripheral blood vessels to the heart.

10Occlutech Sizing Balloon
CategoryImplant Delivery Accessories
Description

Balloon catheter used to measure the size of cardiac defects such as ASD and PFO prior to device selection and implantation.

11Occlutech Stiff Guide Wire
CategoryImplant Delivery Accessories
Description

Guide wire providing stiffness and support for catheter navigation during Occlutech device implantation procedures.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1B. Braun Interventional Systems Inc.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-05-01
Description

Exclusive distribution partnership for the US market. B. Braun Interventional Systems assumes commercialization activities for the Occlutech ASD Occluder and Occlutech Pistol Pusher, with support from the Occlutech global team. The partnership leverages B. Braun's established interventional cardiology and congenital heart disease channel presence. Signed in May 2022, with B. Braun initiating commercialization following FDA approval in December 2023.

us.occlutech.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

V-Wave is developing interatrial shunt devices (Ventura Shunt) for heart failure patients, directly competing with Occlutech's AFR in the same novel therapeutic category targeting HFpEF and HFrEF populations.

TypeEmerging player
Description

SentreHEART developed LARIAT and related left atrial appendage closure technologies serving structural heart patients, an adjacent peer with overlapping interventional cardiology customer relationships and physician call points.

3Abbott
TypeBroad incumbent
Description

Abbott owns the Amplatzer portfolio (Amplatzer Septal Occluder, PFO Occluder, etc.), the dominant global franchise in transcatheter cardiac defect closure that directly competes with Occlutech's occluder devices across all major markets and serves as the benchmark for physician adoption.

TypeDirect peer
Description

Corvia Medical is developing the InterAtrial Shunt Device (IASD) for heart failure with preserved ejection fraction (HFpEF), directly competing with Occlutech's Atrial Flow Regulator (AFR) in the same interatrial shunting therapeutic category.

TypeBroad incumbent
Description

Boston Scientific is a major cardiovascular device company with structural heart and interventional cardiology offerings, including competitive occluder technologies and a broad sales channel that overlaps with Occlutech's target hospital accounts.

TypeEmerging player
Description

Alleviant Medical is developing a transcatheter interatrial shunt device for heart failure (No-Implant Approach), competing with Occlutech's AFR with a differentiated technology that creates an alternative path in the same therapeutic market.

TypeDirect peer
Description

pfm medical produces Nitinol-based cardiac occluders (e.g., Nit-Occlud, CERA) for ASD and PFO closure in European and emerging markets, directly competing with Occlutech's Nitinol occluder portfolio using similar material science.

TypeDirect peer
Description

Lifetech Scientific manufactures and markets a range of cardiac occluders (Cera, HeartR, etc.) for ASD, PFO, PDA, and VSD closure, directly competing with Occlutech's occluder portfolio particularly in Asia-Pacific and emerging markets.

TypeDirect peer
Description

Gore Medical produces the GORE CARDIOFORM Septal Occluder for ASD closure and the GORE CARDIOFORM PFO Occluder, directly competing with Occlutech's PFO and ASD occluders in the US and European markets with comparable transcatheter delivery systems.

TypeEmerging player
Description

Cardia Innovation develops PFO and ASD occluder devices using Nitinol technology, an emerging competitor in the structural heart closure space targeting similar interventional cardiology customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Occlutech

Cardiac Implantsocclutech.com

Occlutech is a medical device company that develops and commercializes minimally invasive Nitinol-based cardiac implants, including occluders for congenital heart defects and the Atrial Flow Regulator for heart failure, serving interventional cardiologists across approximately 85 countries.

What Occlutech does

Occlutech is a medical device company founded in 2003 that develops, manufactures, and commercializes minimally invasive cardiac implants based on proprietary Nitinol braiding technology. The company is legally domiciled in Switzerland as Occlutech Holding AG, with finance and distribution operations in Helsingborg, Sweden, and manufacturing and R&D facilities in Jena, Germany, and Istanbul, Turkey. Its product portfolio spans three therapeutic areas: Congenital Heart Disease (ASD, PDA, mVSD occluders), Adult Intervention and Stroke Prevention (PFO, UNI, PLD occluders), and Heart Failure (the Atrial Flow Regulator, an interatrial shunting device). Differentiated design features include a left-atrial hubless ASD Occluder and conformable braided wire architecture protected by over 200 patents.

The company sells directly in France, Germany, Italy, the Nordics, and the United Kingdom, and through a distribution partner network spanning approximately 85 countries, with over 220,000 occluders implanted across more than 70 countries. In the United States, Occlutech commercializes the ASD Occluder exclusively through B. Braun Interventional Systems Inc. following FDA approval in December 2023. Revenue is generated through per-unit hardware sales of implants and delivery accessories, supported by clinical evidence dissemination, medical congress presence, and physician education. 2025 unaudited revenue was EUR 49.4 million with approximately 85% derived from Europe and the US, representing a 15.7% CAGR over three years.

Customer segments include pediatric and adult patients with congenital heart defects, adult patients at risk of cryptogenic stroke, and heart failure patients with preserved or reduced ejection fraction who remain symptomatic despite optimal medical therapy. The company is positioning for accelerated US expansion and a potential heart failure indication for the AFR, supported by the FROST-HF pivotal study and FDA Breakthrough Device designation. A binding agreement announced in February 2026 for Alkem MedTech to acquire up to 55% of Occlutech Holding AG for EUR 99.4 million, at a total equity value of EUR 180.7 million, represents a major ownership transition expected to close by June 2026 and provide additional capital and strategic backing from Alkem Laboratories.

Occlutech firmographics

Firmographics
Name
Occlutech
Legal name
Occlutech Holding AG
Website
https://occlutech.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
Occlutech is a medical device company that develops and commercializes minimally invasive Nitinol-based cardiac implants, including occluders for congenital heart defects and the Atrial Flow Regulator for heart failure, serving interventional cardiologists across approximately 85 countries.
Ownership category
akta.pro rank

Occlutech industry classification

Industry
Product category
Cardiac Implants
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAL
Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac occluder devices
  • Structural heart implants
  • Nitinol medical devices
  • Transcatheter cardiac devices
  • Congenital heart disease treatment

Where Occlutech is headquartered

Location

Headquarters

HQ city
Helsingborg
HQ country
Sweden
HQ region
Europe

Offices5 records

Markets served

Occlutech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Medical Device Sales: Occlutech generates revenue through the sale of its proprietary cardiac implants and delivery accessories. Products include occluders (ASD, PFO, PDA, mVSD, UNI, PLD) and the Atrial Flow Regulator (AFR). Revenue is derived from direct sales in key European markets and through distribution partners globally, with a growing US market following FDA approval of the ASD Occluder in 2023.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Occlutech product offering

Product offering

Core offering

Occlutech designs, manufactures, and commercializes minimally invasive cardiac implants built on proprietary Nitinol braiding technology. Its portfolio includes occluders for congenital heart defects (ASD, PDA, mVSD), adult intervention occluders (PFO, UNI, PLD), and the Atrial Flow Regulator (AFR) for heart failure treatment, supported by delivery system accessories. Products are sold directly to hospitals and interventional cardiologists in key European markets and through distributor networks covering approximately 85 countries.

Product overview

Occlutech offers a broad portfolio of minimally invasive cardiac implants designed to address three main therapeutic areas: Congenital Heart Disease, Stroke Prevention & Adult Intervention, and Heart Failure. The product portfolio centers on occluder devices (ASD, PFO, PDA, mVSD, UNI, PLD) for closing various cardiac defects, and the Atrial Flow Regulator (AFR) for heart failure treatment. Supporting accessories include delivery systems (Pistol Pusher, Delivery Set III), sizing balloons, and guide wires. The company operates with a proprietary Nitinol-based braided wire technology and self-centering design across its device range. Products are sold in approximately 85 countries with manufacturing and R&D facilities in Germany and Turkey.

Differentiator

Problem solved

Functional benefit

Brands

  • Atrial Flow Regulator (AFR): Cardiac implant designed to address unmet needs of heart failure patients through interatrial shunting
  • ASD Occluder
  • PFO Occluder
  • PDA Occluder
  • mVSD Occluder
  • UNI Occluder
  • PLD Occluder

Products and services

  • ASD Occluder Self-centering occluder for percutaneous transcatheter closure of ostium secundum-type atrial septal defects, featuring double discs with waist and flexible wire design for conformable deployment. Sold in over 70 countries with 220,000+ occluders implanted globally.
  • PFO Occluder Occluder device for closure of Patent Foramen Ovale (PFO) to prevent cryptogenic stroke by closing the flap-like opening between the atria in adult patients.
  • PDA Occluder Minimally invasive transcatheter closure device for Patent Ductus Arteriosus (PDA), featuring an aortic disc connected to a conical-shaped shank made of braided Nitinol.
  • mVSD Occluder Occluder device designed for transcatheter closure of muscular ventricular septal defects (mVSD), a type of congenital heart defect.
  • UNI Occluder Universal occluder device for various cardiac defect closures, part of Occlutech's adult intervention portfolio.
  • PLD Occluder Occluder device for patent ductus ligation (PLD) procedures, part of Occlutech's adult intervention product portfolio.
  • Atrial Flow Regulator (AFR) CE-marked cardiac implant for interatrial shunting in heart failure patients with preserved (HFpEF) or reduced (HFrEF) ejection fraction who remain symptomatic despite optimal medical therapy. Two-disc configuration with central fenestration for controlled left-to-right atrial shunt. Available in two waist-heights, disc sizes, and fenestration diameters.
  • Occlutech Pistol Pusher Delivery system accessory for precise placement and deployment of the ASD Occluder device during transcatheter procedures.
  • Occlutech Delivery Set III Delivery catheter system for implanting Occlutech occluder devices through peripheral blood vessels to the heart.
  • Occlutech Sizing Balloon Balloon catheter used to measure the size of cardiac defects such as ASD and PFO prior to device selection and implantation.
  • Occlutech Stiff Guide Wire Guide wire providing stiffness and support for catheter navigation during Occlutech device implantation procedures.

Quantifiable outcome

  • Higher rate of successful defect closure with less major complications vs. comparator device in randomized trial (Kenny et al., Catheter Cardiovasc Interv 2019)
  • +4 more outcomes

Companies that use Occlutech

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles1 record

Occlutech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Occlutech partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • B. Braun Interventional Systems Inc.coreChannel Partner/ Reseller/ Distributor · 1 May 2022Exclusive distribution partnership for the US market. B. Braun Interventional Systems assumes commercialization activities for the Occlutech ASD Occluder and Occlutech Pistol Pusher, with support from the Occlutech global team. The partnership leverages B. Braun's established interventional cardiology and congenital heart disease channel presence. Signed in May 2022, with B. Braun initiating commercialization following FDA approval in December 2023.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Occlutech competitors and assessment

Company assessment

Direct peers

  • V-Wave: V-Wave is developing interatrial shunt devices (Ventura Shunt) for heart failure patients, directly competing with Occlutech's AFR in the same novel therapeutic category targeting HFpEF and HFrEF populations.
  • Corvia Medical: Corvia Medical is developing the InterAtrial Shunt Device (IASD) for heart failure with preserved ejection fraction (HFpEF), directly competing with Occlutech's Atrial Flow Regulator (AFR) in the same interatrial shunting therapeutic category.
  • pfm medical: pfm medical produces Nitinol-based cardiac occluders (e.g., Nit-Occlud, CERA) for ASD and PFO closure in European and emerging markets, directly competing with Occlutech's Nitinol occluder portfolio using similar material science.
  • Lifetech Scientific: Lifetech Scientific manufactures and markets a range of cardiac occluders (Cera, HeartR, etc.) for ASD, PFO, PDA, and VSD closure, directly competing with Occlutech's occluder portfolio particularly in Asia-Pacific and emerging markets.
  • W. L. Gore & Associates (Gore Medical): Gore Medical produces the GORE CARDIOFORM Septal Occluder for ASD closure and the GORE CARDIOFORM PFO Occluder, directly competing with Occlutech's PFO and ASD occluders in the US and European markets with comparable transcatheter delivery systems.

Emerging players

  • SentreHEART: SentreHEART developed LARIAT and related left atrial appendage closure technologies serving structural heart patients, an adjacent peer with overlapping interventional cardiology customer relationships and physician call points.
  • Alleviant Medical: Alleviant Medical is developing a transcatheter interatrial shunt device for heart failure (No-Implant Approach), competing with Occlutech's AFR with a differentiated technology that creates an alternative path in the same therapeutic market.
  • Cardia (Cardia Innovation): Cardia Innovation develops PFO and ASD occluder devices using Nitinol technology, an emerging competitor in the structural heart closure space targeting similar interventional cardiology customers.

Broad incumbents

  • Abbott: Abbott owns the Amplatzer portfolio (Amplatzer Septal Occluder, PFO Occluder, etc.), the dominant global franchise in transcatheter cardiac defect closure that directly competes with Occlutech's occluder devices across all major markets and serves as the benchmark for physician adoption.
  • Boston Scientific: Boston Scientific is a major cardiovascular device company with structural heart and interventional cardiology offerings, including competitive occluder technologies and a broad sales channel that overlaps with Occlutech's target hospital accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Occlutech social profiles

Digital presence

Occlutech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Occlutech leadership team

Management profile

Number of profiles

Profiles10 records

Occlutech subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Occlutech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Occlutech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Occlutech

What does Occlutech do?

Occlutech designs, manufactures, and commercializes minimally invasive cardiac implants built on proprietary Nitinol braiding technology. Its portfolio includes occluders for congenital heart defects (ASD, PDA, mVSD), adult intervention occluders (PFO, UNI, PLD), and the Atrial Flow Regulator (AFR) for heart failure treatment, supported by delivery system accessories. Products are sold directly to hospitals and interventional cardiologists in key European markets and through distributor networks covering approximately 85 countries.

Is Occlutech a public or private company?

Occlutech is a private company. It is classified as venture growth investor backed and is currently operating.

When was Occlutech founded?

Occlutech was founded in 2003. It employs 101 to 250 people.

Where is Occlutech based?

Occlutech is headquartered in Helsingborg, Sweden, in the Europe region.

How does Occlutech make money?

One revenue line is on record: medical Device Sales.

Who are Occlutech's main competitors?

Direct peers on record are V-Wave, Corvia Medical, pfm medical, Lifetech Scientific and W. L. Gore & Associates (Gore Medical). Emerging players are SentreHEART, Alleviant Medical and Cardia (Cardia Innovation). Broad incumbents are Abbott and Boston Scientific.

Does Occlutech have an API?

No public API is recorded for Occlutech.

What industry is Occlutech in?

Occlutech's product category is Cardiac Implants. Its primary akta.pro industry code is HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation), with a secondary code of HLAHAFAJ, Thrombectomy, Embolic Protection & Stroke Intervention Devices. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WhalesbookAlkem Labs Infuses ₹1,100 Crore into Subsidiary for Occlutech AcquisitionAlkem Laboratories Ltd. has infused approximately ₹1,100 crore into its wholly-owned subsidiary, Alkem Medtech Private Limited, through a rights issue of 79,36,50,794 equity shares at ₹13.86 per share, with shares allotted on July 15, 2026. The capital will be used by Alkem Medtech to acquire a controlling 51-55% stake in Occlutech Holding AG, marking Alkem's strategic expansion from pharmaceuticals into the medical device sector, specifically cardiovascular and orthopedic fields. This acquisition aims to establish an international market presence for Alkem Laboratories, though investors should monitor execution risk given Alkem Medtech's limited operational history with only ₹15.13 crore turnover in FY26.Medical BuyerAlkem Medtech to acquire 51% stake in Occlutech HoldingAlkem Medtech, a subsidiary of Alkem Laboratories, has executed a First Supplementary Agreement to acquire between 51% and 55% of Occlutein Holding AG, a Swiss medtech company, with the agreement signed on June 26, 2026. This marks a significant step forward in the acquisition process that was initially announced in February and March 2026. The transaction aligns with Alkem Medtech's strategic objective of expanding its footprint in the medtech sector through targeted acquisitions.ScanXAlkem Medtech Signs Pact to Acquire 51%-55% Stake in Occlutech Holding AGAlkem Medtech Private Limited, a wholly owned subsidiary of Alkem Laboratories Ltd, executed a First Supplementary Agreement on June 26, 2026, to acquire a 51%–55% stake in Switzerland-based Occlutech Holding AG, modifying the original Share Purchase Agreement from March 6, 2026. The acquisition is part of Alkem Laboratories' broader expansion strategy and follows earlier disclosures made in February and March 2026. Key questions remain regarding financing, regulatory approvals from Swiss authorities, and whether Alkem plans to launch a mandatory open offer for the remaining shares.startupticker.chOcclutech to gain Alkem as majority shareholderIndian pharmaceutical company Alkem MedTech has announced plans to acquire up to a 55% majority stake in Swiss medtech company Occlutech for EUR 99.4 million, with closing expected by June 2026. Occlutech develops minimally invasive cardiac devices and ranks as the second-largest company in Europe and third-largest globally in this segment, reporting 2025 unaudited revenue of EUR 49.4 million with approximately 85% derived from Europe and the US. The acquisition represents Alkem MedTech's strategic entry into advanced cardiovascular devices and is subject to regulatory approvals and customary closing conditions.ET NOWDividend Stock: 1973 pharma company; Rs 43 cash reward for shareholders - Record date on Feb 20Alkem Laboratories Ltd declared an interim dividend of Rs 43 per equity share for FY 2025-2026, with a record date of February 20, 2026 and payment from March 6, 2026. The company reported a 1.9% rise in Q3 consolidated net profit at Rs 653.03 crore and consolidated revenue of Rs 3,736.82 crore. Additionally, Alkem Laboratories signed a binding term sheet to acquire a majority stake in Swiss medical devices firm Occlutech Holding AG at an equity value of 180.7 million euros.https://www.outlookbusiness.com/Alkem Laboratories Q3 Net Profit Rises 1.9% at ₹653.03 Cr, to Acquire 55% Stake in Occlutech – Outlook BusinessAlkem Laboratories Ltd reported a 1.9% rise in consolidated net profit at Rs 653.03 crore for Q3 FY25 ended December 31, 2025, with total revenue from operations at Rs 3,736.82 crore; India sales grew 5.5% to Rs 2,495.9 crore while international sales rose 26.6% to Rs 1,215.7 crore. The company has signed a binding term sheet to acquire a 55% majority stake in Swiss medical devices firm Occlutech Holding AG at a total equity value of 180.7 million euros, marking its entry into the cardiovascular segment as part of Alkem MedTech's strategic expansion.Business StandardAlkem MedTech to acquire 55% stake in Occlutech for €99.4 millionAlkem MedTech, the medical devices division of Alkem Laboratories, has announced a binding offer to acquire a 55% controlling stake in Switzerland-based Occlutech Holding AG for €99.4 million (approximately Rs 1,074 crore), with completion expected by June 2026 pending regulatory approvals. Occlutech, founded in 2003, is the second-largest player in Europe and third-largest globally in the minimally invasive cardiac implants segment, reporting unaudited revenues of €49.4 million in calendar year 2025 with a 15.7% compound annual growth rate over three years. The acquisition marks Alkem MedTech's strategic entry into the global structural heart devices market, transitioning beyond its current orthopaedic implants focus into advanced cardiovascular devices with manufacturing operations across Germany, Turkey, Sweden, and the United States.BusinessLineAlkem Laboratories Q3 net profit rises 1.9% at ₹653.03 cr, to acquire 55% stake in OcclutechAlkem Laboratories reported a 1.9% rise in consolidated net profit at ₹653.03 crore for Q3 ended December 31, 2025, with consolidated revenue from operations at ₹3,736.82 crore. The company signed a binding term sheet to acquire a 55% majority stake in Swiss medical devices firm Occlutech Holding AG at a total equity value of 180.7 million euros. India sales grew 5.5% to ₹2,495.9 crore while international sales surged 26.6% to ₹1,215.7 crore, supporting the company's strategic expansion into cardiovascular medical devices through its Alkem MedTech division.Business StandardAlkem MedTech to acquire 55% stake in Occlutech for €99.4 millionAlkem MedTech, the medical devices arm of Alkem Laboratories, has announced the acquisition of a 55% majority stake in Switzerland-based Occlutech Holding AG for €99.4 million (approximately Rs 1,074 crore), marking its entry into the global structural heart devices segment. Occlutech, founded in 2003, is the second-largest player in Europe and third-largest globally in minimally invasive cardiac implants, with unaudited revenues of €49.4 million in calendar year 2025 and a 15.7% compound annual growth rate over three years. The transaction, expected to close by June 2026 pending regulatory approvals, represents a strategic shift for Alkem MedTech beyond its current orthopaedic implants focus into advanced cardiovascular devices with high regulatory barriers and strong pricing power.